AZZ Inc. reported strong operating performance with notable revenue and adjusted EBITDA growth, led by a 22.9% increase in its Metal Coatings segment. Despite robust underlying profitability and cash flow, GAAP results are skewed by previous joint venture gains. The Precoat Metals segment improved margins, though demand across end markets remains mixed. The company raised guidance, but due to slowing growth forecasts and a valuation 19–26% above historical averages, the analyst maintains a Hold rating.
AZZ's strong quarter is notable amid a Basic Materials sector where only 14 of 83 US stocks rose. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 14, 2026 21:32 WIB: USAR (USA Rare Earth Inc. Class A Common Stock) traded at USD 10.57 with a 1-day change of -6.17%, CDE (Coeur Mining Inc. Common Stock) at USD 15.27 down 6.09%, and USAS (Americas Gold and Silver Corporation Common Shares) at USD 3.79 down 5.85%.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
